NovoCure

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public oncology company with over 1,000 employees. The company has raised $742 million across five funding rounds and went public on NASDAQ in October 2015. In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing.

Business overview

NovoCure is a commercial-stage oncology company focused on developing Tumor Treating Fields (TTFields), a novel, proprietary therapy for solid tumor cancers. TTFields utilize low-intensity, intermediate-frequency alternating electric fields to disrupt cell division processes, leading to cell death. The therapy is delivered via noninvasive, insulated transducer arrays connected to a portable electric field generator, designed for continuous wear. NovoCure serves the healthcare and life sciences sectors, targeting patients and providers with its medical technologies, particularly in cancer treatment.

Strategic signal

In September 2024, NovoCure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as his successor. This leadership change signals a strategic evolution for the company, potentially indicating a shift in operational focus or a new phase of corporate development as it continues to advance its Tumor Treating Fields therapy.

Company Intelligence Q&A

What is NovoCure's primary therapeutic focus?

NovoCure develops Tumor Treating Fields (TTFields), a proprietary therapy that uses low-intensity, intermediate-frequency alternating electric fields to disrupt cell division in solid tumor cancers.

When did NovoCure go public?

NovoCure went public on NASDAQ in October 2015, raising $165 million with an initial valuation of $1.8 billion.

What significant financing did NovoCure secure in 2024?

In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing.

What recent leadership change occurred at NovoCure?

In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor.

What recent regulatory approval did NovoCure receive in Japan?

In September 2025, NovoCure's Optune Lua® received approval in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).